KALY - Kali-Extracts Analyst Report Published On OTCMarkets Augmenting Current Information
January 08 2019 - 11:00AM
InvestorsHub NewsWire
KALY - Kali-Extracts Analyst Report
Published On OTCMarkets Augmenting Current Information
Dallas, TX
-- January 8, 2019 -- InvestorsHub NewsWire -- Kali, Inc.
(dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published an independent analyst research
report on the company following the recent acquisition of a
patented cannabis extraction process. The report is available
under “research” on the OTCMarkets website. The research report is the
first report from Goldman Small Cap Research as part of an ongoing
research engagement. The report outlines the company’s current
positioning and potential, upcoming milestones. This report is
intended to augment the current information available on the
OTCMarkets website. KALY has recently updated all of its financial
reports required by OTCMarkets to satisfy the OTCMarkets “current”
filing standards and anticipates the OTCMarkets site to soon
reflect Kali’s “current” filing status. As of the publication of
this release, OTCMarkets has yet to update this status. All
quotation information cited in the report was derived from Yahoo!Finance which reports Kali intraday
trading activity and news. While quote information is not available
on OTCMarkets website pending the filing status update, investors
and shareholders can alternatively obtain current quote information
on Yahoo!Finance or from their own online
brokerage account.
The report is
also available to read or download, along with associated
disclosures and disclaimers, at www.GoldmanResearch.com.
Kali
Report Highlights
Kali, Inc. is a
health and wellness company set to generate revenue from its
patented cannabis extraction technology through overlapping
go-to-market strategies to include the licensing of its patented
cannabis extraction technology to multiple companies in the
wellness and pharmaceutical industries. With promising preclinical
data along with development and commercial agreements behind it,
Kali-Extracts seeks to commercialize its unique and valuable IP
targeting multi-billion dollar markets. The recent legalization of
hemp farming in the 2018 Farm Act just signed into law by President
Trump puts the wind at Kali’s back.
The Company’s
multi-pronged approach is divided into two target categories:
Pharmaceuticals and Wellness.
Goldman
highlighted the key segments in his research
report.
“In the
pharmaceutical space, Kali has completed an in vitro genomics study
to evaluate the impact of its pharmaceutical grade cannabis
extracts in combination with other therapies on COPD patients.
Favorable results prompted the launch of a physiological study
whose results will be released in 1Q19. The World Health
Organization estimates 65 million people worldwide are afflicted
with moderate to severe COPD and GlobalData forecasts that the COPD
treatment market will reach $14.1 billion by
2025.”
“In the wellness
arena, the early affirmation of its extract’s efficacy has occurred
via sales of Puration Inc.’s (USOTC:
PURA) CBD-infused product which is based on Kali’s IP. Various
joint ventures in which Kali has engaged are likely sources of near
term revenue for Kali in the CBD-infused product market, projected
to grow to $22 billion in the next few years. Plus, these
relationships could result in additional business opportunities
going forward. All told, Kali believes it could generate $5 million
or more in revenue from specific endeavors with current
partnerships.”
About
Goldman Small Cap Research: Founded in 2009 by former
Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman
Small Cap Research produces sponsored and non-sponsored small cap
and microcap stock research reports, articles, stock market blogs,
and popular investment newsletters.
Goldman Small
Cap Research is not in any way affiliated with Goldman Sachs &
Co.
This press
release contains excerpts of our most recently published report on
Kali, Inc. The information provided in the report was for
information use only and may have contained forward-looking
statements along with statements of fact that may have been
obtained from sources considered reliable. Thus, we neither
guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon
information derived from press releases issued by and due diligence
related to management of Kali, Inc. some of which are referred to
in authorized press releases or legal disclosures made in its
filings with the U.S. Securities and Exchange Commission
http://www.sec.gov.
Separate from the factual content of our report, we
may from time to time include our own opinions about the Companies,
its business, markets and opportunities. Any opinions we may offer
about the Companies are solely our own, and are made in reliance
upon our rights under the First Amendment to the U.S. Constitution,
and are provided solely for the general opinionated discussion of
our readers. Our opinions should not be considered to be complete,
precise, accurate, or current investment advice. Statements herein
and in the report may contain forward-looking statements and are
subject to significant risks and uncertainties affecting
results.
It should be
noted that Kali has recently updated all of its financial reports
required by OTCMarkets to satisfy the OTCMarkets “current” filing
standards and anticipates that the OTCMarkets site to soon reflect
Kali’s “current” filing status. As of the report publication date,
OTCMarkets has yet to update this status. All quotation information
cited in the report was derived from Yahoo!Finance which reports
Kali intraday trading activity and news.
A Goldman Small
Cap Research report, update, newsletter, article, trading alert,
corporate profile, podcast interview or press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell the securities mentioned or discussed
is to be used for informational purposes
only. Please read all associated full disclosures,
disclaimers, and analyst background on our website before
investing. Neither Goldman Small Cap Research nor its parent is a
registered investment adviser or broker-dealer with FINRA or any
other regulatory agency. To download or view the Kali report or any
of our research on Puration, Inc., or other sponsored research,
please view our disclosures and disclaimers, or for more
information, visit www.goldmanresearch.com.
Goldman Small
Cap Research was compensated $3500 by the Company for the
publication of this report. It should be noted that during 2018,
GSCR was compensated by Puration, Inc. in the amount of $5500 for a
research subscription service and a previous podcast
interview.
About
Kali, Inc. (OTC
- KALY) Kali, Inc. is a health and wellness company
set to generate revenue via licensing its patented cannabis
extraction technology to multiple companies in the wellness and
pharmaceutical industries. With promising preclinical data along
with development and various commercial agreements behind it, Kali,
Inc. seeks to commercialize its unique and valuable IP targeting
multi-billion-dollar markets.
For more
information, please visit: www.kali-extracts.com
Goldman Small
Cap Research
Rob Goldman,
Analyst
410-609-7100
rob@goldmanresearch.com
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2024 to Jun 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jun 2023 to Jun 2024